SafeSEQ Panel

HPV-SEQ Test

The HPV-SEQ test is a clinical grade, ultra-sensitive liquid biopsy solution for the identification and quantification of circulating HPV 16 and HPV 18 DNA in patients with cancers caused by HPV infection, including cervical cancer, anal squamous cell carcinoma, and head and neck squamous cell cancer. HPV-SEQ detects cell-free HPV DNA (cfHPV-DNA) across a large dynamic range and demonstrates accurate quantification even when few copies are present, enabling high-resolution molecular monitoring.

The SafeSEQ HPV Test detects HPV copies across a broad range of levels, and demonstrates low variability even when few copies are present, which enables high-resolution molecular monitoring. This image shows a vial with patient plasma, HPV DNA, and human genomic cfDNA.

Clinical Relevance

HPV causes several different malignancies, including cervical cancer, anal squamous cell carcinoma, and head and neck squamous cell carcinoma. For example, HPV 16 causes the majority of oropharyngeal cancer in the United States1. HPV DNA detection in plasma using the SafeSEQ HPV Test enables precise tracking of disease burden and response to therapy in patients with HPV associated cancer.

References

1. Chera BS, Kumar S, Shen C, Amdur R, et al. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. J Clin Oncol. 2020; 38(10):1050-1058. doi: 10.1200/JCO.19.02444. Epub 2020 Feb 4. Erratum in: J Clin Oncol. 2020 Oct 20;38(30):3579. PMID: 32017652; PMCID: PMC7106982.

More Ultra-sensitive SafeSEQ Panels

Interested in learning more about our ultra-sensitive SafeSeq Panels?